

Quarter 2

SPRING 2023

Metabolic Effects of Antipsychotics in Pediatric Patients

Both first generation (typical) and second generation (atypical) antipsychotics are dopamine receptor antagonists; second generation antipsychotics have a higher affinity for serotonin receptors compared to first generation.^{1,2} Second generation antipsychotics are the preferred agents for adult and pediatric patients due to their increased efficacy for negative symptoms of psychoses and decreased incidence of extrapyramidal side effects.^{2,3}

Antipsychotics bind with varying selectivity to alpha, histamine, muscarinic, and serotonin receptors leading to differences in adverse effect profiles within the class.^{1,2} Antipsychotics can cause metabolic adverse effects in 60% of patients, including metabolic syndrome which consists of increased waist circumference, dyslipidemia, insulin resistance, and hypertension.³ Metabolic syndrome increases the risk of type 2 diabetes mellitus, heart disease, and stroke.³ The risk of metabolic effects increases with younger age, antipsychotic naïve patients, and longer duration of therapy.³

There has been an increase in antipsychotic use in pediatrics, including off-label uses for attention deficit hyperactivity disorder and depression.^{3,4} Few clinical trials evaluate the efficacy and safety of antipsychotics for off-label uses in the pediatric population and further research is needed to evaluate their role in these instances.^{3,4}

The risk of metabolic effects increases with younger age, antipsychotic naïve patients, and longer duration of therapy.³

Patient-centered treatment with antipsychotics should include evaluation of guideline recommendations, alternatives to antipsychotics including behavior interventions, and risk of metabolic effects versus anticipated benefit.³ Health care providers should counsel patients and their family members prior to initiating therapy on benefits and risks of treatment and lifestyle modifications to reduce risk of metabolic effects.^{3,4} Patients on antipsychotics should undergo baseline and regular monitoring of personal and familial history, modifiable risk factors, weight, body mass index, waist circumference, blood pressure, heart rate, fasting glucose, hemoglobin A1c, and fasting lipid profiles.³ The reversibility of weight gain from antipsychotic use is unclear and further research is needed.³ In the event of significant weight gain, prescribers should evaluate the benefits and risks of continuing or switching agents and implement non-pharmacological and pharmacological interventions for weight management if needed.³

Studies have shown that metabolic monitoring occurs less frequently during antipsychotic treatment for pediatric patients.³ Regular monitoring is vital for efficacy and safety in pediatric patients due to their increased risk of metabolic effects.³

References:

1. *Antipsychotic agents, first generation (typical)*. Drug Facts and Comparisons [Internet]. 2020. [cited 2023 Jun 20]. Available from: https://fco.factsandcomparisons.com/lco/action/doc/retrieve/docid/fc_dfc/5546134
2. *Antipsychotic agents, second generation (atypical)*. Drug Facts and Comparisons [Internet]. 2023. [cited 2023 Jun 20]. Available from: https://fco.factsandcomparisons.com/lco/action/doc/retrieve/docid/fc_dfc/5546135
3. Libowitz MR, Nurmi EL. The burden of antipsychotic-induced weight gain and metabolic syndrome in children. *Front Psychiatry* [Internet]. 2021 Mar 12 [cited 2023 Jun 20];12:623681. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994286/>
4. *Atypical antipsychotic medications: Use in pediatric patients* [Internet]. 2015 [cited 2023 Jun 20]. Available from: <https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/atyp-antipsych-pediatric-factsheet11-14.pdf>

North Dakota Medicaid Pharmacy Program Quarterly News

Published Quarterly by Kepro

The “North Dakota Medicaid Pharmacy Program Quarterly News” is a pharmacy newsletter presented by the North Dakota Department of Health and Human Services and published by Kepro. This newsletter is published as part of a continuing effort to keep the Medicaid provider community informed of important changes in the North Dakota Medicaid Pharmacy Program.

The North Dakota Department of Health and Human Services has contracted with Kepro to review and process prior authorizations (PAs) for medications. For a current list of medications requiring a PA, as well as the necessary forms and criteria, visit www.hidesigns.com/ndmedicaid, or call Kepro at (866) 773-0695 to have this information faxed. An important feature on this website is the NDC Drug Lookup, which allows you to determine if a specific NDC is covered (effective date), reimbursement amount, MAC pricing, copay information, and any limitations (prior authorization or quantity limits).

The North Dakota Medicaid Pharmacy Program team appreciates your comments and suggestions regarding this newsletter. To suggest topics for inclusion, please contact Kepro at 1-800-225-6998, or e-mail us at ND_Info@kepro.com.



Helpful Numbers:

PA Help Desk	866-773-0695
To fax Pas	855-207-0250
To report adverse reactions	800-FDA-1088

Stay Informed:

Quarter 3 Newsletter:
Medication Therapy Management
Hepatitis C Criteria Updates

DUR Board Meeting:
Wednesday, September 6, 2023
1:00 PM